Susanna Meade

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Simeng Lin, Nicholas A. Kennedy, Aamir Saifuddin et al. · Nature Communications · 2022 · 81 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

RAND appropriateness panel to determine the applicability of UK guidelines on the management of acute respiratory distress syndrome (ARDS) and other strategies in the context of the COVID-19 pandemic

Mark Griffiths, Susanna Meade, Charlotte Summers et al. · Thorax · 2021 · 40 citations · Full text

Medicine, Internal Medicine, Critical Care Respiratory Therapy +16

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study

Zhigang Liu, Kaixing Le, Xin Zhou et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 35 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel

Shahida Din, Alexandra Kent, Richard Pollok et al. · Gut · 2020 · 32 citations · Full text

Medicine, Infectious Diseases, Internal Medicine +8

Pituitary metastases: presentation and outcomes from a pituitary center over the last decade

Kirstie Lithgow, Izel Siqueira, Latha Senthil et al. · Pituitary · 2020 · 31 citations · Full text

Medicine, Endocrinology, Oncology +17